The Coolest Cardiac Ablation Technologies
Adagio's portfolio is based on ultra-low temperature cryoablation (ULTC) designed to produce large, durable lesions extending through the depth of both diseased and healthy cardiac tissue., by itself, or with the added benefit of cardiac electroporation (Pulsed Field Cryoablation or PFCA).
FUNDAMENTALS OF ULTCFUNDAMENTALS OF PFCA
Transcatheter ultra-low temperature cryoablation (ULTC) is Adagio's Medical proprietary technology. As compared to other commercially-available catheter cryoablation technologies which utilize N2O refrigerant at Tb = -88.50C and rely on slow cell dehydration for lesion formation, ULTC utilizes "near-critical" N2 flow at Tb=-1960C to rapidly cool target heart cells to temperatures consistent with formation of intracellular ice and almost instantaneous death. Unique feature of ULTC technology is it's ability to produce broad variety of contiguous transmural lesions in both atria and ventricles using a single ablation cycle.
Adagio Medical Ultra-Low Temperature VT Cryoablation System with vCLAS™ Cryoablation System is CE-Mark approved for treatment of monomorphic ventricular tachycardia.
Adagio Medical Ultra-Low Temperature VT Cryoablation System with vCLAS™ Cryoablation System is CE-Mark approved for treatment of monomorphic ventricular tachycardia.
